LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

18.66 -3.27

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.57

Máximo

18.88

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	507
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+90.45% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-42M 2.9B
Abertura anterior	21.93
Fecho anterior	18.66

Sentimento de Notícias

By Acuity

76%

24%

311 / 345 Ranking em Healthcare

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 de mai. de 2026, 23:42 UTC

Conversa de Mercado

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 de mai. de 2026, 23:11 UTC

Conversa de Mercado

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 de mai. de 2026, 22:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 de mai. de 2026, 22:11 UTC

Conversa de Mercado

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 de mai. de 2026, 22:04 UTC

Conversa de Mercado

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

90.45% parte superior

Previsão para 12 meses

Média 35.5 USD 90.45%

Máximo 42 USD

Mínimo 23 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

311 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.